Contraceptive Technology Update – June 1, 2003
June 1, 2003
View Issues
-
Get ready to take cervical cancer screening to the next level
It is estimated some 50 million women in the United States are screened on an annual basis with Pap tests. Clinicians now have another tool in their arsenal that will help distinguish women at increased risk of developing cervical cancer from those at very low risk. -
FemCAP method receives market approval from the Food and Drug Administration
Your next patient is a young married woman who is unable to use hormonal birth control and is not interested in using an intrauterine device. Because she wants to have more children, sterilization is not an option at the present time. What contraceptive methods are available to her? -
Hormone therapy: Does it boost quality of life?
New research from the Womens Health Initiative (WHI) indicates that for many postmenopausal women, combined hormone therapy does not have a clinically significant effect on their health-related quality of life. -
Does EC impact contraceptive use?
When it comes to emergency contraception (EC), does its availability and use impact ongoing contraceptive methods? Initial research from one study indicates that adolescent mothers who are given a supply of EC are no less likely to use condoms and other forms of birth control than teen mothers who are not given EC. -
Treatment options narrow for gonorrhea
With fluoroquinolone-resistant gonorrhea becoming more common in the United States, clinicians have looked to two treatment alternatives, cefixime and ceftriaxone, to combat the sexually transmitted disease (STD). -
Guest Column: New research confirms efficacy of NuvaRing
Since the NuvaRing contraceptive vaginal ring (Organon, West Orange, NJ) entered the U.S. market in mid-2002, new research has been published that underscores its efficacy and acceptability.